Duration and compostion of dual antiplatelet therapy has been increasingly changed within the past few years as also indicated in the firmer ESC guidelines. The current manuscript summarizes the most important changes in dual antiplatelet therapy as shown by a recent ESC position paper and offers quick insight into these new developments.
Keywords: Acute coronary syndromes; Atrial fibrillation; Dual antiplatelet therapy; P2Y12-inhibitors; Stable coronary artery disease.